Safety in Regenerative Aesthetics

Cornelius (Neil) Pybis BA, DipHE, INP asks: are we moving faster than the evidence?

Over the last  14 years working in aesthetic medicine, I have witnessed enormous change within our profession. Treatments that were once considered innovative have become commonplace, and procedures that once generated scepticism are now accepted parts of everyday clinical practice.

When I first entered aesthetics, much of the conversation centred around restoring volume, softening lines and addressing visible signs of ageing. Today, however, the language has changed. Increasingly, practitioners and patients are talking about regeneration, tissue repair, cellular rejuvenation and biostimulation.

In many ways, this evolution is exciting. As clinicians, most of us would prefer to improve skin quality rather than simply disguise ageing. The idea that we can support the skin’s own repair mechanisms, improve tissue health and potentially influence the ageing process at a biological level is an attractive proposition for both practitioner and patient.

However, as regenerative aesthetics continues to grow, I find myself asking an important question: are we moving faster than the evidence?It is a question I believe our profession must be willing to ask if patient safety is to remain at the centre of what we do.

The rise of regenerative aesthetics

There is no doubt that regenerative medicine has become one of the most talked-about areas within aesthetic practice.

Polynucleotides, PDRN-based products, biostimulatory injectables, exosomes, growth factors and increasingly sophisticated energy-based devices are all being positioned as part of the regenerative movement.

Patients are becoming increasingly knowledgeable. Many arrive at consultations having researched treatments online and are often specifically seeking procedures that promise healthier, stronger, and younger-looking skin.

In my own clinic, I have noticed a significant shift in patient expectations over recent years. Patients are asking fewer questions about simply filling wrinkles and more questions about skin quality, collagen stimulation and long-term tissue health. This is undoubtedly a positive development.

Natural outcomes have become increasingly desirable, and many patients are looking for subtle improvements rather than dramatic transformations.

However, demand can sometimes drive innovation faster than science can keep pace.

The challenge of marketing

One of the greatest challenges facing practitioners today is separating scientific evidence from marketing language.

Every year, new products arrive on the market claiming to stimulate collagen, regenerate tissue, improve cellular function, or reverse aspects of ageing. Many of these products may indeed have genuine clinical value. The difficulty is determining which claims are supported by robust evidence and which are primarily promotional. As a practitioner, I am increasingly cautious when I encounter phrases such as:

• Cellular regeneration
• Stem-cell activation
• Tissue reconstruction
• Age reversal
• Biological renewal

These terms sound impressive, but what do they actually mean? More importantly, what evidence supports them? In medicine, language matters.

A claim of improved hydration is very different from a claim of tissue regeneration. Likewise, supporting collagen production is not necessarily the same as reversing the ageing process.

As clinicians, we have a responsibility to understand these distinctions before communicating them to patients.

Asking better questions

One lesson I have learned throughout my nursing and aesthetic career is that patient safety often depends on asking the right questions.

When a new regenerative product is introduced, I believe practitioners should look beyond the marketing brochure. 

I want to know:

• What is the regulatory status of the product?
• Is there a clear Instructions for Use?
• Is there published clinical evidence?
• What adverse events have been reported?
• Is there appropriate traceability?
• Does my professional indemnity insurance cover its use?
• What support is available if complications occur?

These questions are not barriers to innovation. They are safeguards.

Unfortunately, social media can sometimes create an environment where asking questions is viewed as negativity rather than professionalism. I would argue the opposite. The safest practitioners are often those who ask the most questions.

The evidence gap

One of my concerns within regenerative aesthetics is that product adoption can sometimes occur before substantial independent evidence becomes available. This does not necessarily mean products are unsafe. It simply means we should be honest about the level of evidence supporting them. 

There is a significant difference between:

• Biological plausibility
• Early clinical observations
• Manufacturer-sponsored studies
• Independent peer-reviewed evidence

These categories are often blended together in marketing conversations, but from a clinical perspective, they are very different. As practitioners, we must avoid assuming that promising science automatically translates into proven patient outcomes. History has shown us many examples where early enthusiasm was later tempered by further investigation.

That is how science should work.

• Evidence evolves.
• Knowledge develops.
• Clinical understanding improves.

The problem occurs when commercial enthusiasm outruns scientific validation.

Education remains essential

As both a clinician and educator, I remain convinced that education is the strongest protection we have against poor decision-making. Modern aesthetic practice requires far more than technical injection skills. Practitioners must understand anatomy, physiology, pharmacology, product science, complication management, consent and regulation.

Regenerative aesthetics introduces another layer of complexity because many products are marketed on biological mechanisms that are still being investigated and understood. The future practitioner must therefore be capable of critically evaluating evidence rather than simply accepting claims at face value.

In my view, evidence appraisal will become one of the most important skills in aesthetic medicine over the next decade.

Looking forward

I remain optimistic about the future of regenerative aesthetics. There is genuine innovation taking place within our sector. New technologies and products have the potential to improve patient outcomes and expand our understanding of how skin health can be supported over time.

However, innovation should never replace critical thinking. The most successful treatments of the future will not necessarily be those supported by the largest marketing budgets. They will be those supported by robust evidence, transparent governance and well-trained practitioners.

For me, patient safety remains the benchmark against which every new treatment should be measured. Not what is fashionable. Not what is trending. Not what generates the greatest excitement online. What matters is whether we can confidently demonstrate that a treatment is safe, appropriate and beneficial for our patients.

As regenerative aesthetics continues to evolve, I believe our profession has an opportunity to lead by example. We can embrace innovation while remaining scientifically responsible.

We can remain open-minded without becoming uncritical. And most importantly, we can ensure that patient welfare remains at the heart of every decision we make. In aesthetics, progress should never be measured solely by what is possible. It should also be measured by what is safe. Only then will regenerative medicine realise its true potential and earn the confidence of both practitioners and patients alike.